lung cancer
Generated by GPT-5-miniExpansion Funnel Raw 55 → Dedup 0 → NER 0 → Enqueued 0
| lung cancer | |
|---|---|
| Name | Lung cancer |
| Field | Pulmonology, Oncology |
| Symptoms | Cough, hemoptysis, weight loss |
| Complications | Metastasis, respiratory failure |
lung cancer Lung cancer is a group of malignant neoplasms originating in the pulmonary parenchyma and airways, notable for high morbidity and mortality worldwide. It is managed across specialties including American Society of Clinical Oncology, National Comprehensive Cancer Network, World Health Organization, and influences public health policy in nations such as the United States, United Kingdom, China, and India. Landmark studies from institutions like Johns Hopkins Hospital, Mayo Clinic, Dana-Farber Cancer Institute, and Memorial Sloan Kettering Cancer Center have shaped modern understanding and care.
Classification and Histology
Classification relies on histologic subtype and cell morphology using criteria from entities such as the World Health Organization and staging systems developed by the American Joint Committee on Cancer. Major categories include non-small cell subtypes—adenocarcinoma, squamous cell carcinoma, large cell carcinoma—and small cell carcinoma. Adenocarcinoma shows glandular differentiation and mucin production, often described in reports from Royal College of Pathologists and studied in cohorts at Harvard Medical School and Stanford University School of Medicine. Immunohistochemistry panels referencing markers validated by laboratories at Mayo Clinic and Cleveland Clinic distinguish subtypes; molecular testing for alterations recognized by European Society for Medical Oncology is routine.
Epidemiology and Risk Factors
Incidence and mortality are tracked by agencies including the Centers for Disease Control and Prevention, Cancer Research UK, and the International Agency for Research on Cancer. Tobacco exposure from products regulated in countries like the United States and China is the dominant risk factor; passive smoke exposure and occupational carcinogens identified by Occupational Safety and Health Administration and International Labour Organization—such as asbestos and radon—also elevate risk. Geographic patterns observed in registries maintained by SEER Program and Global Burden of Disease Study show variation by sex and socioeconomic status, while genetic predisposition studies from National Institutes of Health and academic centers like University of California, San Francisco identify familial syndromes and germline variants.
Pathophysiology and Molecular Biology
Tumorigenesis involves oncogenic drivers and tumor suppressor loss characterized in landmark projects such as The Cancer Genome Atlas and validated in trials at Memorial Sloan Kettering Cancer Center. Common molecular alterations include mutations in genes profiled by laboratories at Broad Institute and Wellcome Sanger Institute—notably EGFR, ALK rearrangements, KRAS, TP53, and ROS1 fusions. Pathways implicated overlap with signaling cataloged by National Cancer Institute programs and targeted by drugs developed by pharmaceutical companies like Roche, AstraZeneca, and Pfizer. Tumor microenvironment interactions, immune evasion mechanisms studied in trials at MD Anderson Cancer Center and biomarkers such as PD-L1 expression guide immunotherapy decisions.
Clinical Presentation and Diagnosis
Patients frequently present with respiratory and systemic symptoms documented in clinical guidelines from Royal College of Physicians, American Thoracic Society, and European Respiratory Society. Common findings include persistent cough, hemoptysis, dyspnea, and paraneoplastic syndromes described in case series from Johns Hopkins Hospital and Massachusetts General Hospital. Diagnostic evaluation uses imaging modalities produced by vendors studied at Mayo Clinic—chest radiography, computed tomography, positron emission tomography—and tissue diagnosis obtained via bronchoscopy techniques refined at Guy's and St Thomas' NHS Foundation Trust and endobronchial ultrasound programs at Bellevue Hospital. Molecular profiling for actionable targets follows protocols from National Comprehensive Cancer Network and laboratory accreditation standards from College of American Pathologists.
Staging and Prognostic Factors
Staging employs the TNM classification promulgated by the American Joint Committee on Cancer and the Union for International Cancer Control. Prognosis is influenced by stage at diagnosis, performance status measures such as the Karnofsky score developed at Memorial Sloan Kettering Cancer Center, tumor histology, and molecular features including EGFR and ALK status identified in multicenter trials coordinated by groups like the Eastern Cooperative Oncology Group. Imaging for staging often includes CT and PET-CT scans reported by centers such as Royal Marsden Hospital and invasive mediastinal staging via mediastinoscopy techniques with origins traceable to procedures performed at St Thomas' Hospital.
Treatment and Management
Management integrates surgery, radiation, systemic therapy, and palliative care coordinated among institutions like MD Anderson Cancer Center, Cleveland Clinic, and UCLA Health. Early-stage disease is often treated with lobectomy pioneered in surgical series from Mayo Clinic and stereotactic body radiotherapy protocols developed at University of Texas Southwestern Medical Center. Systemic options include cytotoxic chemotherapy regimens evaluated in randomized trials from groups such as National Cancer Institute cooperative groups, targeted agents for EGFR and ALK developed by AstraZeneca and Pfizer, and immune checkpoint inhibitors approved based on trials led by teams at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. Multidisciplinary frameworks endorsed by National Comprehensive Cancer Network and survivorship programs at Mount Sinai Health System address symptom control, rehabilitation, and end-of-life care.
Prevention and Screening
Primary prevention efforts are driven by public health initiatives from the World Health Organization, Centers for Disease Control and Prevention, and tobacco control policies inspired by measures adopted in Australia and Canada. Smoking cessation programs evaluated in trials at Vanderbilt University Medical Center and pharmacologic interventions developed by companies like GlaxoSmithKline reduce incidence. Low-dose CT screening for high-risk populations follows recommendations from trials such as the National Lung Screening Trial coordinated by the National Cancer Institute and implementation guidance from U.S. Preventive Services Task Force and Canadian Task Force on Preventive Health Care.